CRINETICS PHARMACEUTICALS Trademark
Trademark Overview
On Friday, March 17, 2023, a trademark application was filed for CRINETICS PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the CRINETICS PHARMACEUTICALS trademark a serial number of 97844252. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Saturday, May 17, 2025. This trademark is owned by Crinetics Pharmaceuticals, Inc.. The CRINETICS PHARMACEUTICALS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders,...
Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye dis...
General Information
| Serial Number | 97844252 |
| Word Mark | CRINETICS PHARMACEUTICALS |
| Filing Date | Friday, March 17, 2023 |
| Status | 819 - SU - REGISTRATION REVIEW COMPLETE |
| Status Date | Saturday, May 17, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, January 30, 2024 |
Trademark Statements
| Description of Mark | The mark consists of the word "CRINETICS" above the word "PHARMACEUTICALS" with a dot and line spirograph design in the shape of a half circle starting above the letter "I" in "CRINETICS" and wrapping around the first letter "C" in "CRINETICS". |
| Goods and Services | Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| NOT AVAILABLE | PHARMACEUTICALS |
| Goods and Services | Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 9, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | Friday, December 7, 2018 |
| First Use In Commerce Date | Friday, December 7, 2018 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, April 9, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Wednesday, May 12, 2021 |
| First Use In Commerce Date | Wednesday, May 12, 2021 |
Trademark Owner History
| Party Name | Crinetics Pharmaceuticals, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Party Name | Crinetics Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
Trademark Events
| Event Date | Event Description |
| Tuesday, March 21, 2023 | NEW APPLICATION ENTERED |
| Sunday, April 9, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, April 11, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Monday, October 9, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Wednesday, December 13, 2023 | ASSIGNED TO EXAMINER |
| Monday, December 18, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, December 18, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Monday, December 18, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, December 19, 2023 | ASSIGNED TO LIE |
| Monday, October 9, 2023 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Tuesday, December 19, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Friday, December 22, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, January 30, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 30, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, January 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, February 28, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, February 28, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, February 28, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, March 26, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, September 12, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Thursday, September 12, 2024 | USE AMENDMENT FILED |
| Thursday, September 12, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, September 12, 2024 | SOU EXTENSION 1 GRANTED |
| Thursday, September 12, 2024 | SOU EXTENSION 1 FILED |
| Thursday, September 12, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 31, 2025 | STATEMENT OF USE PROCESSING COMPLETE |
| Saturday, May 17, 2025 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Saturday, May 17, 2025 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
